Q-omics provides the consensus-scored RHBDL3 profile across patient tissues and cancer cell-line models. RHBDL3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RHBDL3 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, RHBDL3 RNA expression shows 18,261 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, BLCA, and THYM as cancer lineages where RHBDL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RHBDL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RHBDL3 survival associations across molecular data types. RHBDL3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RHBDL3 RNA expression–survival associations across cancer types. High RHBDL3 expression shows unfavorable associations in UVM and ACC, but favorable associations in PAAD, HNSC, LGG and COAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RHBDL3 RNA expression.
This table summarizes RHBDL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RHBDL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RHBDL3 shows lower tumor expression in BLCA, KIRC, KIRP and COAD and higher tumor expression in LIHC and LUSC. The BLCA box plot shows higher RHBDL3 RNA expression in normal versus tumor tissue (log2 FC = −0.801, t-test p = .005).
This table shows molecular features associated with RHBDL3 in patient tissues and cancer cell lines. In patient samples, RHBDL3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RHBDL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
